KDR and cancer: The results of the present study add to this controversial effect by supporting 3-indolacetic acid as an inhibitor of angiogenesis, since it inhibits VEGF-induced VEGFR-2 activation (IC50 = 970.4 μM) as another alternative to target cancer cells.